Ipilimumab (anti-CTLA-4)

Catalog No.A2001 Synonyms: MDX-010, BMS-734016, Yervoy

For research use only.
Not for use in humans.

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

Ipilimumab (anti-CTLA-4)

Selleck's Ipilimumab (anti-CTLA-4) has been cited by 8 Publications

Purity & Quality Control

Choose Selective Immunology & Inflammation related Inhibitors

Biological Activity

Description Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.
CTLA-4 [1]
(Cell-free assay)
In vitro

Ipilimumab (anti-CTLA-4), is a fully humanized IgG1k monoclonal antibody produced by recombinant DNA technology in a CHO mammalian cell expression system, binding with high affinity to the extracellular domain of human (and Cynomolgus monkey) CTLA-4, and acting as an inhibitor of its complex functions. This essentially results in T-cell activation and proliferation, and in lymphocyte infiltration leading to tumor cell death. However, the enhancement of T effector cell function, combined with the inhibition of CD4+ Treg and CD8+ suppressive cell types, are considered essential for mediating the full therapeutic effects of ipilimumab[2]. Ipilimumab can improve ATC proliferation, enhance the BiAb-mediated tumor-specific cytotoxicity, and increase cytokine synthesis, while it attenuates Treg activity as shown by decreased level of IL-10 secretion and reduced Treg population[3]. Ipilimumab and nivolumab treatments could collaboratively enhance effector and memory T cell responses without inappropriately activating naive T cells[4].

In vivo Ipilimumab (anti-CTLA-4) is shown in phase III clinical trials to have a survival benefit in metastatic melanoma that is durable in 10% to 20% of patients. Conceivably, the main adverse effects of ipilimumab are autoimmunein nature[1]. Ipilimumab enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg)[3].

Protocol (from reference)

Cell Research:
  • Objective: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
    Cells: PBMC from healthy individuals; COLO356/FG (Pancreatic Cancer cell line) and Burkitt's lymphoma cell line
    Concentrations: 0, 0.5, 5.0, and 50 μg/mL
    Incubation Time: 10-14 days
    Method: hPBMC were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt’s lymphoma cell line (Daudi).
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/25008236

    Objective: Ipilimumab potentiate IL-2 release in SEB-Stimulated Human PBMC
    Cells: hPBMC
    Concentrations: 10 μg/mL
    Incubation Time: 1 h
    Method: PBMC from normal healthy leukophoresis donors were seeded at 1×105 cells/well and stimulated with superantigen staphylococcal enterotoxin B (SEB) serially diluted 30-fold from 2.5 μg/mL. Ipilimumab, Nivolumab or huIgG4 isotype control was present at a spike concentration of 10 μg/mL. IL-2 secretion was measured by ELISA on day 3.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/27610613

    Ipilimumab can apply to humanized mice (eg:NSG mice), peripheral blood and other related assays (Only for Reference)

Animal Research:
  • Objective: To investigate whether Ipilimumab and PD-1 antibody enhance the ability of T cells to control the outgrowth of EBV-induced lymphomas
    Animal Models: NSG mice (humanized mice) were injected (i.p.) with EBV infected human cord blood mononuclear cells (Commercially purchased from AllCells)
    Formulation: PBS
    Dosages: 100 μg, three times weekly
    Administration: i.p.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/27186886

    Objective: In vivo characterization of Ipilimumab T cell modulation and antitumor activity in a tumor bearing humanized NSG mouse model
    Animal Models: NSG mice (humanized mice) were injected human peripheral blood mononuclear cells (PBMCs).Then implanted subcutaneous with human A2058 melanoma and 786-O renal adenocarcinoma cell lines
    Formulation: --
    Dosages: twice weekly
    Administration: i.p.
    Reference: http://cancerimmunolres.aacrjournals.org/content/4/1_Supplement/A054.short

    Ipilimumab can apply to humanized mice (eg:NSG mice), peripheral blood and other related assays (Only for Reference)

Product Details

CAS No. 477202-00-9
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How to store the antibody?

Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.

Tags: buy Ipilimumab (anti-CTLA-4) | Ipilimumab (anti-CTLA-4) supplier | purchase Ipilimumab (anti-CTLA-4) | Ipilimumab (anti-CTLA-4) cost | Ipilimumab (anti-CTLA-4) manufacturer | order Ipilimumab (anti-CTLA-4) | Ipilimumab (anti-CTLA-4) distributor